Merck joins consortium on vax plant

Merck, IBM and Battelle have signed up to partner with GE Healthcare on a new vaccine plant that has been proposed by the University of Pittsburgh Medical Center. The vaccine facility backers want to build a state-of-the-art facility that can respond on an emergency basis to bioterror attacks. Merck would contribute its drug-development expertise, with IBM handling IT and Battelle doing the pre-clinical work and research. Story

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.